Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome

NCT04776746 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT04776746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 8, 2020
Completion date
June 30, 2023
Enrollment
77 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome